More patients with amyotrophic lateral sclerosis (ALS) had a positive response to an injection of an experimental stem cell therapy developed by Brainstorm Cell Therapeutics (BCLI) compared to similar ALS patients given a placebo, according to results from a U.S. clinical trial announced Monday. But on other efficacy measures, including change in the rate of ALS disease progression and lung function, no differences were observed between the placebo patients and those treated with Brainstorm's stem cell therapy, known as NurOwn. NurOwn emerged from the study with a clean safety profile, so even with mixed efficacy results, there is enough scientific justification to advance the stem cell...
↧